Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Clarivate Identifies the Role of Research and Innovation in the World’s Shift to Sustainable Energy

Published

on

 

Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released a new report, A study of energy in transition: the role of research and innovation in the world’s shift to sustainable energy sources. It finds that innovation activity in the sustainable energy space is tailing off, as research and inventive activities for respective renewable develops at different paces. This finding is based on Clarivate data normalized for overall increases in scientific journal and patent output increases globally in all subject areas.

According to the report, solar photovoltaic and wind power, two of the eight categories of renewable energy sources based on the EU Sustainable Finance Taxonomy, have seen the greatest volume of research and inventive activity in the past three decades, but that activity is tailing off1. This indicates that the two sustainable energies approached development maturity, where the most complex technological issues and challenges have been solved.

Oceanic power generation currently falls within the immature scale of the report’s sustainable energy sources maturity index,2 despite oceanic power, with its high energy density, being seen as one of the most promising sustainable energy sources if fully harnessed.

From a geographic perspective, Mainland China tops global research and innovation output in renewable energy sources, strengthening its international stature as a research and innovation powerhouse. While the United States and Mainland China are closely matched in terms of cumulative scientific research output for renewable energy sources, Mainland China’s cumulative inventive activity for renewable energy sources far exceeds that of the U.S. Patent activity for renewable energy in Mainland China is, however, not keeping pace with overall Mainland Chinese patent activity, which is accelerating.3 This supports the report’s analysis that research and innovation activity in the sustainable energy space is tailing off.

“This study is part of our contribution towards the UN Sustainable Development Goal 9: Industry, Innovation and Infrastructure. It looks at the relationship between global research and innovation in the roll out and development of sustainable energy sources. It identifies current gaps, trends and needs of further research concentration, while looking at where capabilities lie, by sustainable energy source and geography,” said Tiffani ShawChief of Staff and Sustainability Sponsor, Office of the CEO, Clarivate.

Other key findings of the report include:

  • Renewable non-fossil fuels, which include green hydrogen, have experienced among the lowest level of inventive and foundational research activity to date.
  • Top five countries/regions for inventive impact: Mainland China, Saudi ArabiaCanadaUnited States and Switzerland4India has made great strides, with the highest increase in inventive strength.
  • Top five countries/regions for top 1% citation impact in scientific articles: AustraliaSwitzerlandNetherlandsSaudi Arabia and Canada.5

Ed White, Chief Analyst and VP, IP and Innovation Research at Clarivate said, “Securing a habitable, sustainable planet for future generations is one of the world’s most pressing concerns. Our study provides innovation intelligence to bridge the information gap between ambition and action – so that funders, corporations, governments and researchers can better understand the state of the current research and innovation ecosystem for renewable energy sources and its likely future shape.  In doing so, we enable them to support decision making to accelerate the shift to sustainable energy.”

White concluded, “The current energy crisis has added a sense of urgency to the world’s efforts to transition to sustainable energy. Policy makers can take the answers uncovered by the world’s scientists and match their governments’ sustainable energy ambitions with tangible action. At Clarivate, our broad range of curated insights – from scientific and academic research to IP intelligence – coupled with deep analytical expertise, can help the world make sense of complex issues, such as the state of our world’s transition to sustainable energy sources, providing answers for the way forward to a better, sustainable energy-powered future.”

Methodology
Rigorous data surrounding global research and innovation was collated and curated for this report, bringing together the deep content of the Web of Science™ publisher independent global citation database, the curated source of global patent data from the Derwent World Patent Index™ (DWPI™), the Derwent Patents Citation Index and global IP case data from Darts-ip™. Through a new data collection process reliant on the patent examination process where references to research papers are incorporated in the collection definition and then expanded into a peer group of related, relevant research, a “base” knowledge ecosystem enabling sustainable energy technologies was formed. The research base and the trends within it were measured, alongside the direct technology development cycles within patented technologies specific to sustainable energy sources.

Artificial Intelligence

Ancoris Recognised as Top Place to Work for Second Year Running by The Sunday Times

Published

on

ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times

Ancoris recognised for fostering a sense of empowerment and respect within the workplace91% of Ancoris employees feel empowered at work93% of employees say that are treated with respectLONDON, May 21, 2024 /PRNewswire/ — Ancoris, a UK-based Google Cloud services provider, has been named a Top Medium Business in The Sunday Times 2024 Best Places to Work list. The accolade has been awarded for the second year in a row, and recognises Ancoris’ focus on DEI; its commitment to empowerment, reward, and recognition; and its wellbeing policies and frameworks.

“I am so pleased to see Ancoris recognised, once again, as a top place to work!” says Andre Azevedo, Ancoris CEO. “Ancoris is a place where we try our best to foster collaboration, empowerment, innovation, and respect – so to have our employees echo this and respond in the way they have is amazing.”
The Sunday Times survey captured Ancoris employees’ responses in a number of categories: Reward and Recognition, Information Sharing, Empowerment, Wellbeing, Instilling Pride, and Job Satisfaction. The independently managed survey showed Ancoris scoring “excellent” across all six engagement categories, with top scores in Empowerment, Wellbeing, Reward & Recognition. In response, 93% of employees say they are treated with respect; 92% feel trusted and able to make decisions; and 91% of employees feel empowered at work.
“We’ve seen a lot of change over the last 12 months. The rise of Generative AI has caused shifts in our market and  economic conditions are causing customers to really qualify where they make technology investments. These pivots undoubtedly have an impact on our employees and how people feel at work,” Azevedo continues. “I truly believe, however, the innovative work we are doing for our customers has helped us maintain and create an even stronger sense of collaboration and pride for our team members. We’re lucky to have so many smart people within our business, so continuing to give them interesting, challenging, and rewarding problems to solve for our customers is really key.”
About AncorisAncoris is a leading Google Cloud Services Provider, headquartered in the UK, on a mission to become the most innovative Google Cloud partner in the ecosystem. Ancoris leverages its strong problem solving skills and continuous improvement approach to help customers become AI Native and stay ahead of their competition. Ancoris has extensive experience in Google Cloud technologies helping enterprises integrate AI-native solutions into their business through expertise in Data & AI, Application and Infrastructure Modernisation, Workspace, and Maps. Ancoris was recognized as a Rising Star for Data, Analytics, and Machine Learning in the ISG Provider™ Lens for Google Cloud Partner Ecosystem in 2022 and 2023 consecutively, and awarded Google Cloud’s 2024 EMEA Public Sector Partner of the Year award. Ancoris employs the best in the business and was named in the Top 10 Sunday Times Best Places to Work 2023, and a Top Place to Work in 2024.
Contact: Holly [email protected]
Photo – https://mma.prnewswire.com/media/2417995/Ancoris_Sunday_Times.jpgLogo – https://mma.prnewswire.com/media/2099949/4717512/Ancoris_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times-302151325.html

Continue Reading

Artificial Intelligence

Department of Health – Abu Dhabi Partners with Roche Pharmaceuticals Middle East to Elevate Research, Clinical Trials, and Real-World Data

Published

on

department-of-health-–-abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research,-clinical-trials,-and-real-world-data

ABU DHABI, UAE, May 21, 2024 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week (ADGHW). Under the MoU, the two entities will advance critical research using real-world data to study and assess the spinal muscular atrophy burden in Abu Dhabi, as well as assessing potential conduction of research and the facilitation of real-world data collection to monitor Duchenne Muscular Dystrophy (DMD) disease.

 
 
In the presence of Dr. Rashed Alsuwaidi, the Executive Director of the Healthcare Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Abu Dhabi has a track record of excellence and fast-growing, future-forward, data-enabled services. Serving as a hub for healthcare data, Abu Dhabi’s substantial computing power enables it to harness the potential within this data, transforming it into valuable information. This, in turn, allows us to innovate and develop novel approaches to shift healthcare towards prediction, prevention, and treatment, thereby accelerating the future of healthcare, not only for Abu Dhabi but for the global community. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as expand access to quality care for patients around the world.”
The two entities will work together to support the evolution of real-world data collection frameworks in Abu Dhabi. Enhancing DoH’s ability to track and monitor outcomes of therapies will support DoH in making informed clinical and policy decisions for better optimisation of patient outcomes. Furthermore, DoH and Roche will strengthen the research network across Abu Dhabi and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE said: “This MoU underscores our collaboration with the DoH which is fuelled by a shared vision of harnessing the power of data to drive informed decision-making within the healthcare system. Data-driven healthcare systems hold immense potential to revolutionise patient care and outcomes. Through the generation, utilisation, and realisation of data, healthcare professionals and policymakers can unlock valuable insights, identify trends, and make evidence-based decisions. This data-driven approach enables us to optimise resource allocation, personalise treatment approaches, and ultimately achieve better patient outcomes. By harnessing the full potential of data, we can improve the overall efficiency and effectiveness of the healthcare system, ensuring that every patient receives the highest quality of care tailored to their specific needs. We are sincerely grateful for the trust, confidence, and empowerment the DoH has placed in establishing this effective public-private partnership with Roche in the UAE.”
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, ADGHW is a major government initiative by the DoH, which took place from the 13th -15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
Photo – https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html

Continue Reading

Artificial Intelligence

Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe

Published

on

biopharma-leaders-shape-the-future-of-drug-development-at-veeva-r&d-and-quality-summit-europe

Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes
BARCELONA, Spain, May 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.

As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.
The event’s zone keynotes include:
Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.Novo Nordisk, showing how it uses data and AI to transform clinical research.Sanofi, explaining its innovative approach to advance quality through operational excellence.Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.
“Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients,” says Rik Van Mol, senior vice president of Veeva Development Cloud. “At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together.”
Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.
Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html

Continue Reading

Trending